# CRIMSON BIOPHARM INC: Targeting EGFR-Mutant NSCLC CNS Metastases with CM93, a Novel Brain-Penetrant EGFR Inhibitor

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | CRIMSON BIOPHARM INC |
| Location | Brookline, MA |
| Project | Targeting EGFR-Mutant NSCLC CNS Metastases with CM93, a Novel Brain-Penetrant EGFR Inhibitor |
| Project number | 2R42CA281586-02 |
| Mechanism | R42 |
| Institute | National Cancer Institute |
| Award | $1,125,000 |
| Awarded | 2026-09-17 |
| Project period | 2026-09-22 to 2028-08-31 |
| UEI | ZPMLH22W5Y81 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11408851). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.